-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Lowered to $41 at BofA Securities
-
-
-
-
-
-
-
Agios Pharma (AGIO): 'Aqvesme's opportunity in thalassemia reason enough to own the stock,' says analyst
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Raised to $62 at H.C. Wainwright
-
-
-
-
-
-
-
Agios Pharma's (AGIO) Regulatory Path in the Air - Cantor Fitzgerald
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)
-
-
-
-
-
-
-
TD Cowen on Agios Pharma (AGIO): 'we view an extension rather than issuance of a CRL as a positive sign'
-
-
-
-
-
-
-
Agios Pharma (AGIO) Misses Q2 EPS by 12c
-
416,806 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

